Correction: Current status of human biomonitoring of beauvericin and enniatins - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Updated overview of human biomonitoring for beauvericin and enniatins

  • By

  • Gisela H. Degen

  • Anamarija Romac

  • November 13, 2026

Share

Objective:

To correct errors in the published article.

Approach:
  • Author name: Corrects the first author’s name from “Gsela H. Degen” to “Gisela H. Degen.”
  • Table 2: Corrects the second-line entry in the final column, headed “Kyei et al. 2026,” from “9191.7%” to “91.7% > LOQ.”
Key Findings:
  • A correction has been issued for the article.
Interpretation:

The notice corrects the author’s name and a Table 2 data entry.

Sources:

Original Source(s)

Correction: Current status of human biomonitoring of beauvericin and enniatins

  • by Gisela H. Degen, Anamarija Romac

  • November 13, 2026

Related Content

WHO 2026 global TB report: Mortality misses 2025 target

Global TB deaths fell 35% since 2015, well short of the targeted 75% reduction.

Can PAP resume immediately after sinus surgery?

Patients restarting therapy within 1 day showed no statistically significant adjusted differences in sinonasal healing, bleeding, or patient-reported outcomes.

Artificial Intelligence Use in Interventional Clinical Trials Registered on ClinicalTrials.gov